Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Global Synthetic Hormones Market (2023-2028)" report has been added to ResearchAndMarkets.com's offering.
The analysis projects that the Global Synthetic Hormones Market, valued at USD 0.56 Billion in 2023, is on course to reach a value of USD 1.09 Billion by 2028, indicating a Compound Annual Growth Rate (CAGR) of 14.32%.
This comprehensive report is centered on market dynamics that are identified as critical influencers of price and behavior amongst stakeholders, as well as the generation of pricing signals which arise from shifts in supply and demand curves for a given product or service. These dynamics include various macro and micro-economic factors.
The study delves into the Global Synthetic Hormones Market’s segmentation based on product type, method of administration, application, end-user, and geographic distribution:
By product type, the market comprises Steroid Hormones, Peptide Hormone, Amino Acid Derivatives, and Others. The market's administration methods include Oral, Topical, Nasal, Intravenous, and Suppository. Applications include Growth Hormone Deficiency, Male Hypogonadism, Menopause, and Thyroid Hormone Deficiency. End users consist of Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Geographic distribution includes the Americas, Europe, Middle East & Africa, and Asia-Pacific.
The report also features an in-depth analysis of market competition, providing thorough data on the financial performance of publicly listed companies within the market, as well as comprehensive information on recent developments and the competitive landscape. Some of the companies included in this report are Acerus Pharmaceuticals Corp., American Regent, Inc., BioTE Medical, Endo Pharmaceuticals Inc., Ferring B.V., IBSA Institut Biochimique SA, and Lupin Pharmaceuticals, Inc., amongst others.
The Competitive Quadrant included in the report is a proprietary tool designed to evaluate the position of companies based on their Industry Position score and Market Performance score. This tool analyzes various factors to categorize players into four segments. Factors considered include financial performance over the previous 3 years, growth strategies, innovation score, new product launches, investments, and growth in market share, among others.
The report also presents a detailed Ansoff Matrix analysis for the Global Synthetic Hormones Market. This matrix is a strategic tool used for the growth strategy design of companies. It is also employed for risk analysis to understand the potential risks associated with each approach.
The report includes an in-depth market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. It also covers the impact of COVID-19, and the potential implications of economic slowdown & an impending recession on the market. In addition, the report features a regulatory scenario in the industry, helping you make an informed decision, discussing major regulatory bodies and significant rules and regulations imposed on this sector across various geographies.
Market Dynamics
The dynamics of the Synthetic Hormones Market are influenced by a number of factors. The driving forces include a surge in the occurrence of irregular menstrual cycles, increasing instances of thyroid-related diseases, and a quickening rise in consumer awareness regarding bioidentical hormones. These factors contribute to the market's growth. However, the high cost of synthetic hormones poses a significant challenge, potentially hindering the market's expansion.
Opportunities for growth exist in the oral synthetic hormones segment, which is predicted to progress at a notable rate. Additionally, manufacturers' heightened focus on research and development for new products presents further growth opportunities.
On the other hand, challenges persist, particularly the adverse side effects associated with hormone usage. The ability of market players to navigate these challenges will have a significant impact on the market's trajectory.
Key Attributes:
Report Attribute | Details |
No. of Pages | 215 |
Forecast Period | 2023 - 2028 |
Estimated Market Value (USD) in 2023 | $561.04 Million |
Forecasted Market Value (USD) by 2028 | $1095.48 Million |
Compound Annual Growth Rate | 14.3% |
Regions Covered | Global |
Company Profiles:
- Acerus Pharmaceuticals Corp.
- American Regent, Inc.
- Anhui Anke Biotechnology (Group) Co. Ltd.
- BioPartners, Inc.
- BioTE Medical
- Eli Lilly and Company
- Endo Pharmaceuticals, Inc.
- F. Hoffmann-La Roche
- Ferring B.V.
- GeneScience Pharmaceuticals
- IBSA Institut Biochimique SA
- Ipsen
- Lupin Pharmaceuticals, Inc.
- Lyndra Therapeutics, Inc.
- McGuff Pharmaceuticals, Inc.
- Merck Serono
- Novo Nordisk
- Pfizer, Inc.
- Sandoz International
- Slayback Pharma LLC
- SottoPelle
To find out more about this report, visit https://www.researchandmarkets.com/r/8nhyjf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
![](https://ml.globenewswire.com/media/YTBkMTA3MWEtMWE3My00MTU3LWE1YjktMDU3M2ViOWM0ZGNmLTEwMjY3Mzc=/tiny/Research-and-Markets.png)